Navigation Links
Novocell Appoints Orville G. Kolterman, M.D. to Board of Directors
Date:10/25/2007

SAN DIEGO, Oct. 25 /PRNewswire/ -- Novocell, Inc., a leading stem cell engineering company, today announced the appointment of Orville G. Kolterman, M.D., Senior Vice President, Clinical & Regulatory Affairs of Amylin Pharmaceuticals, to the company's Board of Directors.

Dr. Kolterman joined Amylin in 1992 and has served as Senior Vice President, Clinical Affairs since February 1997 until present and as Senior Vice President, Regulatory Affairs since August 2005. At Amylin, Dr. Kolterman has been instrumental in the development of the company's first-in-class diabetes medicines, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection.

"Dr. Kolterman's breadth of experience, including the clinical development of successful diabetes therapeutics, will be invaluable to Novocell as we advance the development of our diabetes cell therapy and additional cell therapies," said Alan J. Lewis, President, Chief Executive Officer and Director of Novocell.

"I am pleased to join the Novocell board and look forward to working with the Company to help advance it's innovative platform technologies, including its human embryonic stem cell engineering, cell encapsulation and drug discovery efforts, which hold promise for the treatment of a range of chronic diseases," said Dr. Kolterman.

Prior to Amylin, Dr. Kolterman was Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center at the University of California, San Diego (UCSD) Medical Center. He has also served as Assistant Professor of Medicine in the Endocrinology and Metabolism Division at the University of Colorado School of Medicine, Denver and was a member of the Diabetes Control and Complications Trial Study Group. Dr. Kolterman currently serves as a member of the Epidemiology of Diabetes Intervention and Complications Study. He is also a past-president of the California Affiliate of the American Diabetes Association. Dr. Kolterman received his M.D. from Stanford University School of Medicine.

About Novocell

Novocell is a stem cell engineering company with research operations in San Diego, CA, and Athens, GA, dedicated to creating, delivering, and commercializing cell and drug therapies to treat diseases including diabetes. Novocell is the first company to efficiently engineer human embryonic stem cells into definitive endoderm, the gatekeeper cells that differentiate into many other cells, tissues and organs. Novocell is focused on the development of a variety of technology platforms including stem cell engineering, cell encapsulation, and drug discovery. The company was founded in 1999 and merged with CyThera, Inc. and BresaGen, Inc. in 2004. For more information, visit http://www.novocell.com.

Media Contact:

Julie Rathbun

Rathbun Communications, Inc.

julie@rathbuncomm.com

(206) 769-9219


'/>"/>
SOURCE Novocell, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... Personal eye wash is a basic first aid supply for any work ... which eye do you rinse first if a dangerous substance enters both eyes? It’s one ... with its unique dual eye piece. , “Whether its dirt and debris, or an ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading ... a nationwide oncology Clinical Nurse Educator (CNE) network, which will ... need for communication among health care professionals to enhance the ... nurses, office staff, and other health care professionals to help ... breast cancer. ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... maternal age to IVF success. , After comparing the results from the fresh ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):